CAPTRUST Financial Advisors
CRSP icon

CAPTRUST Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,000
Closed -$91 – 2699
2023
Q3 		$91 Buy
+2,000
New +$103K ﹤0.01% 2603

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAPTRUST Financial Advisors's CRSP Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its CRISPR Therapeutics (CRSP) stake by 18% in Q1 2026, buying an estimated $200K and bringing the position to 24,625 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1522.

CAPTRUST Financial Advisors first reported a position in CRSP in Q2 2018 and has held it in 30 quarters since. The position peaked at $3.44M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • CAPTRUST Financial Advisors held 24,625 shares of CRISPR Therapeutics worth $1.17M as of Q1 2026.
  • CAPTRUST Financial Advisors bought 3,800 CRISPR Therapeutics shares in Q1 2026, an estimated $200K.
  • CRISPR Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #1522 holding.
  • CAPTRUST Financial Advisors first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 30 quarters since.
  • CAPTRUST Financial Advisors's CRISPR Therapeutics position peaked at $3.44M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.